Does the PCSK9 rs11591147 (R46L) variant lower LDL cholesterol?

The PCSK9 gene plays a critical role in cholesterol homeostasis, and genetic variations within this pathway significantly influence individual lipid profiles and lifetime cardiovascular risk.

Molecular mechanism

• The rs11591147 polymorphism is a p.Arg46Leu (R46L) missense mutation in the PCSK9 gene that acts as a loss-of-function variant.
• Normally, wild-type PCSK9 protein binds to low-density lipoprotein receptors (LDLR) on hepatocytes and promotes their lysosomal degradation, reducing the cells' ability to clear cholesterol from the blood.
• The R46L substitution disrupts this degradation process, increasing the availability of active cell-surface LDLRs to clear circulating LDL particles.

Clinical and lipid impacts

• Carriers of the rs11591147 variant exhibit a significant, dose-dependent reduction in circulating low-density lipoprotein cholesterol (LDL-C).
• Heterozygous carriers typically experience a 10% to 15% reduction in LDL-C (approximately 11 to 21 mg/dL) compared to non-carriers, while homozygous carriers show reductions of up to 25 to 35 mg/dL.
• This mutation is also associated with broader anti-atherogenic lipid improvements, including lower total cholesterol, lower apolipoprotein B, and fewer small, dense LDL particles.
• Because this genetic effect is present from birth, the resulting lifelong exposure to lower atherogenic lipoproteins translates to a reduced risk of coronary and ischemic heart disease.

Bottom line

• Key takeaway: The PCSK9 rs11591147 (R46L) variant is a highly beneficial loss-of-function mutation that naturally preserves hepatic LDL receptors, resulting in lifelong lower LDL-C levels and a reduced risk of cardiovascular disease.